Online Inquiry


Europe: UK - Germany
Call us at:

Screening for COVID-19 T-cell Peptides and Immune Monitoring with MHC Tetramers

Established in 2004, Creative Biolabs has grown into a thriving CRO collaborating with hundreds of pharmaceutical and biotech companies as well as research laboratories. Empowered by our MHC tetramer production platform, now we extend expertise to explore solutions for the evolving COVID-19.

Coronavirus disease 2019 (COVID-19)

Since last December 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was reported in Wuhan, China. Even though COVID-19 is an acute resolved disease, it can also be deadly, with a 2% case fatality rate. As of Mar 25, about 413,467 cases have been confirmed globally, with 18,433 death cases. Now COVID-19 is an emerging, rapidly evolving situation. It’s critical to discover potential therapy to treat COVID-19.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

SARS-CoV-2 belongs to the Betacoronavirus genus originating from bats. Betacoronaviruses can infect mammals and cause severe respiratory disease after infection in humans. Other virus species in this family include SARS coronavirus and MERS coronavirus. SARS-CoV-2 has approximately 79% sequence identity to SARS-CoV and 50% to MERS-CoV. In addition, homology modeling shows SARS-CoV-2 has a similar receptor-binding domain structure as SARS-CoV, suggesting SARS-CoV-2 also uses the ACE2 receptor for infection in humans. SARS-CoV-2 consists of the following components: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E), a nucleoclapid protein (N) and RNA (see Fig.1).

Structure of SARS-CoV-2.

Fig.1 Structure of SARS-CoV-2.

Screening for COVID-19 T-cell Peptides and Immune Monitoring with MHC Tetramers

In response to the COVID-19 pandemic, Creative Biolabs has developed and launched services to screen for COVID-19 T-cell peptides and monitor the immune responses of potential vaccine with MHC tetramers. After SARS-CoV-2 infection, the processed peptides will be presented by APCs in the context of MHCs. Then the infected cells will be recognized by T cells through the specific T-cell receptor (TCR), resulting in T cell activation and immune activities. Identifying the COVID-19 peptides are valuable to assess vaccine-induced immunity and assist in designing potent vaccines with durable responses.

With extensive experiences and advanced MHC tetramer platform, we can help you identify potential epitopes of SARS-CoV-2 proteins. Also, we can assist you to validate the potential epitopes that can elicit T cell immune responses. We offer screening services in the following MHC alleles: H2Kb, A2, A11, A24, A3 and DR1, DR4, DR15.

We are committed to providing screening services to evaluate hundreds of predicted SARS-CoV-2 peptides for their ability to be presented in the context of MHCs. Our scientists are dedicated to advancing your vaccine development, such as designing and assessing your vaccine.

  • Validating peptide binding affinities to multiple MHC alleles.
  • Identifying and validating promiscuous MHC epitopes.
  • Testing modified peptides for optimal MHC binding and T cell activation.
  • Assessing and monitoring immune responses to individual peptides with MHC tetramers.

Screening for COVID-19 T-cell Peptides and Immune Monitoring with MHC Tetramers

Would you be interested in exploring the research against COVID-19 with Creative Biolabs? Please feel free to contact us to learn how we can be involved in your projects. Let’s work together to find solutions to this novel virus.

All services and products are only for lab research use, not for any clinical diagnosis or treatment.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.